Meet the Authors

Oncology Product Launch Plan and Execution for Rare Disease Indication

Achieving Product Launch Potential for Large Pharma


With the prevalence of cancers increasing, the treatment landscape has also shifted. Oncology drug launches are ever more critical and require a dedicated approach. For this reason, a large biotech and pharma company engaged Herspiegel for their product launch planning for a late oncology entrant in an established category.

The Problem

A biotech and large pharma company partnered with Herspiegel to commercialize a new oncology asset. The launch teams needed a cohesive launch plan reflecting all activities to be completed for launch readiness.

Our Solution

  • Herspiegel evolved a straw-man product launch plan across functions to align to the asset development milestones, market opportunity and strategy.
  • Working sessions were facilitated with the alliance partners to review and finalize the launch plan by function, then a whole team review of the full plan and inter-dependencies was held.
  • Developed and tracked the risk and mitigation plan.
  • Established a governance process for product launches; managing project workstreams and teams to ensure rapid and seamless integration of internal and external stakeholders with timely updates to senior management.



Value Delivered

  • Launch strategies that offered proper direction to a team with competing priorities.
  • Clear and concise plans: delivered detailed strategy, key initiatives, and tactics ensuring alignment and coordination.
  • Successful product launches within a competitive market brand, exceeding revenue goals by ~25%.

Meet the Authors

Let's Talk

Herspiegel is a leading professional services firm helping biotech start-ups and the world’s largest pharmaceutical companies navigate the path from science to brand performance and change patients’ lives. We are committed to using strategic insights from medical to commercial to market access to solve critical problems.